Top

Journal of Thrombosis and Thrombolysis

Published in:

01-04-2010

The association of platelet GPIbα¹⁴⁵Thr/Met (HPA-2a/2b) with myocardial infarction and coronary artery disease

Authors: Marlena Culjak Aleksic, Jasna Mesaric

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2010

Excerpt

To the Editor, …

Pellikka M, Narhi L, Perola M, Penttila A, Karhunen PJ, Mikkelsson J (2008) Platelet GPIbα, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men. J Thromb Thrombolysis 26:91–96. doi:10.1007/s11239-007-0072-2 CrossRefPubMed

Rasmussen R, Morrison T, Herrmann M, Wittwer C (1998) Quantitative PCR by continuous fluorescence monitoring of a double strand DNA specific binding dye. Biochemica (Indianap, Ind) 2:8–11

Hato T, Minamoto Y, Fukuyama T, Fujita S (1997) Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 80:1222–1224. doi:10.1016/S0002-9149(97)00645-0 CrossRefPubMed

Ito T, Ishida F, Shimodaira S, Kitano K (1999) Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol 70:47–51PubMed

Adrissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M (1999) Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94:46–51

Candore G, Piazza G, Crivello A, Grimaldi MP, Orlando V, Caruso M, Caimi G, Hoffmann E, Incalcaterra E, Lio D, Caruso C (2006) Association between platelet glycoprotein Ib-alpha and myocardial infarction: results of a pilot study performed in male and female patients from Sicily. Ann N Y Acad Sci 1089:502–508. doi:10.1196/annals.1386.011 CrossRefPubMed

Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S (1998) Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 90:117–123. doi:10.1016/S0049-3848(98)00042-5 CrossRefPubMed

Ozelo MC, Origa AF, Aranha FJ, Mansur AP, Annichino-Bizzacchi JM, Costa FF, Pollak ES, Arruda VR (2004) Platelet glycoprotein Ib alpha polymorphisms modulate the risk for myocardial infarction. Thromb Haemost 92(2):384–386PubMed

Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V (1998) Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 92:2771–2776PubMed

10.

Mikkelsson J, Perola M, Penttilä A, Karhunen PJ (2001) Platelet glycoprotein Ibα HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 104:876–880. doi:10.1161/hc3301.094907 CrossRefPubMed

11.

Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 96:3281–3286PubMed

12.

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE (2007) Glycoprotein Ib polymorphism T145M, elevated lipoprotein-associated phospholipase A₂ and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients. Diabetes 56:1429–1435. doi:10.2337/db06-1573 CrossRefPubMed

Title: The association of platelet GPIbα145Thr/Met (HPA-2a/2b) with myocardial infarction and coronary artery disease
Authors: Marlena Culjak Aleksic
Jasna Mesaric
Publication date: 01-04-2010
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2010
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-009-0358-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra (Naja naja) venom

The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency

Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension

The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome

Effectiveness of enoxaparin for prevention of radial artery occlusion after transradial cardiac catheterization

Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials